The combination vaccine of HER2/neu-loaded bone marrow-derived dendritic cells (BM-DC) plus QS-21 and anti-PD-L1 monoclonal antibody has demonstrated synergistic antitumor activity and immune response against HER2-positive breast cancer in mice (85). This evidence concerns the gene ERBB2 and breast cancer.